Teresa Montagut to lead Mesoblast (NASDAQ: MESO) clinical and medical affairs

Rhea-AI Filing Summary

Mesoblast Limited reported that Dr. Teresa Montagut, MD, PhD, has been appointed to the newly created role of Head of Clinical Development and Medical Affairs, reporting to Chief Medical Officer Dr. Eric Rose. She will lead medical affairs, clinical collaborations, investigator-initiated trials, and engagement with healthcare professionals.

Dr. Montagut previously held senior medical and development roles at Regeneron, Novartis, Genentech, and Atara Biotherapeutics, and trained at leading U.S. institutions including Memorial Sloan Kettering Cancer Center. The company highlights her importance in advancing Ryoncil®, its FDA-approved mesenchymal stromal cell therapy for pediatric steroid-refractory acute graft versus host disease, and in expanding Mesoblast’s broader inflammatory disease and cell therapy pipeline.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

For the month of March 2026

Commission File Number 001-37626

Mesoblast Limited

(Exact name of Registrant as specified in its charter)

Not Applicable

(Translation of Registrant’s name into English)

Australia
(Jurisdiction of incorporation or organization)

Silviu Itescu

Chief Executive Officer and Executive Director

Level 38

55 Collins Street

Melbourne 3000

Australia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F:

Form 20-F ☑ Form 40-F ☐

INFORMATION CONTAINED ON THIS REPORT ON FORM 6-K

On March 12, 2026, Mesoblast Limited filed with the Australian Securities Exchange a new release announcement, which is attached hereto as Exhibit 99.1, and is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly organized.

Mesoblast Limited

/s/ Paul Hughes

Paul Hughes

Company Secretary

Dated: March 12, 2026

INDEX TO EXHIBITS

Item
99.1						Press release of Mesoblast Ltd, dated March 12, 2026.

DR. TERESA MONTAGUT APPOINTED AS CLINICAL DEVELOPMENT AND MEDICAL AFFAIRS HEAD AT MESOBLAST New York, USA: March 11 and Melbourne, Australia: March 12, 2026: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the appointment of Teresa Montagut MD, PhD in the newly established position of Head of Clinical Development and Medical Affairs reporting to the Chief Medical Officer Dr. Eric Rose. In this role, Teresa will lead Mesoblast’s medical affairs organization, fostering clinical collaborations and spearheading investigator-initiated trials, enhancing clinical and medical communications, and engaging with healthcare professionals. She will play a critical role in unlocking the value of Mesoblast's cell therapy programs in new pediatric and adult inflammatory conditions in partnership with investigators and key opinion leaders. Teresa brings extensive experience in medical leadership and pharmaceutical development, with a strong background in translating clinical science into meaningful patient outcomes. Teresa joined Mesoblast from Regeneron where she was Global Head of Early Pipeline Studies in Oncology and Head of Medical Affairs for Investigator Sponsored Studies in gastrointestinal and genitourinary areas. She previously led multiple cancer immunotherapy programs across Novartis, Genentech, and Atara Biotherapeutics. Teresa earned her MD from Universidad Nacional Autónomade México and her PhD in Tumor Immunology from Memorial Sloan Kettering Cancer Center/Cornell University. She completed fellowships at Massachusetts General Hospital, Howard Hughes Medical Institute, and Rockefeller University. Teresa also serves on the Board of Directors of the Global Pediatric Alliance, supporting maternal and pediatric healthcare in under-served indigenous communities in Latin America, particularly Mexico. “Teri’s commitment to scientific excellence and her expertise in investigator-initiated clinical trial execution is central to successful implementation of our strategy to expand the range of indications of our FDA approved product Ryoncil® in pediatric and adult inflammatory conditions, as well as advancing our pipeline of transformative cellular therapies,” said Dr. Silviu Itescu, Chief Executive Officer of Mesoblast. About Mesoblast Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process. Mesoblast’s Ryoncil® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at www.ryoncil.com. Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Ryoncil® is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China. About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents

and patent applications provide commercial protection extending through to at least 2044 in all major markets. About Mesoblast manufacturing: The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast Release authorized by the Chief Executive. For more information, please contact: Corporate Communications / Investors Paul Hughes T: +61 3 9639 6036 Media – Global Media – Australia Rubenstein BlueDot Media Caroline Nelson Steve Dabkowski T: +1 703 489 3037 T: +61 419 880 486 E: cnelson@rubenstein.com E: steve@bluedot.net.au

FAQ

What executive change did Mesoblast (MESO) announce in this 6-K filing?

Mesoblast announced the appointment of Dr. Teresa Montagut, MD, PhD, as Head of Clinical Development and Medical Affairs. She will oversee medical affairs, foster clinical collaborations, support investigator-initiated trials, and strengthen clinical and medical communications in coordination with the Chief Medical Officer.

What experience does Dr. Teresa Montagut bring to Mesoblast (MESO)?

Dr. Montagut brings extensive medical leadership and pharmaceutical development experience from roles at Regeneron, Novartis, Genentech, and Atara Biotherapeutics. Her background spans early pipeline oncology studies, medical affairs for investigator-sponsored studies, and leading multiple cancer immunotherapy programs across major global biopharmaceutical companies.

What is Mesoblast’s FDA-approved product mentioned in the 6-K filing?

Mesoblast’s FDA-approved product is Ryoncil (remestemcel-L-rknd) for steroid-refractory acute graft versus host disease in pediatric patients two months and older. It is described as the first FDA-approved mesenchymal stromal cell therapy, based on the company’s proprietary mesenchymal lineage cell technology platform.

Which therapeutic areas is Mesoblast (MESO) developing its cell therapies for?

Mesoblast is developing remestemcel-L and rexlemestrocel-L cell therapies for inflammatory diseases and serious conditions. Ryoncil is being developed for adult SR-aGvHD and biologic-resistant inflammatory bowel disease, while rexlemestrocel-L targets heart failure and chronic low back pain in ongoing development efforts.

How strong is Mesoblast’s intellectual property position according to the filing?

Mesoblast states it has over 1,000 granted patents or patent applications worldwide covering mesenchymal stromal cell compositions, manufacturing, and indications. The company notes this intellectual property provides commercial protection extending through at least 2044 across all major markets where it operates.

Where does Mesoblast (MESO) operate and on which exchanges is it listed?

Mesoblast reports locations in Australia, the United States, and Singapore. It is listed on the Australian Securities Exchange under ticker MSB and on Nasdaq under ticker MESO, supporting its global development and commercialization of allogeneic cellular medicines for inflammatory conditions.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EX-99.1 5.9 KB